에토돌락

비스테로이드성 항염증제 (NSAID)

**에토돌락(Etodolac)**은 주로 반려견의 **골관절염**과 관련된 통증 및 염증 관리에 수의학에서 사용되는 비스테로이드성 항염증제(NSAID)입니다. * 경구용 정제 및 주사제 형태로 제공됩니다. * 개에서 비교적 긴 반감기를 가져 편리한 **1일 1회 투여**가 가능합니다. * **임상 요점**: 효과적이긴 하지만 일부 최신 수의용 NSAID에 비해 치료 지수가 좁기 때문에 위장관 독성을 피하려면 정확한 용량 투여가 매우 중요합니다. 치료 용량의 2.7배만 투여해도 위장관 병변이 발생할 수 있습니다.

작용 기전: Etodolac exerts its analgesic, anti-inflammatory, and antipyretic effects primarily by inhibiting the **cyclooxygenase (COX)** enzymes. * **Arachidonic Acid → Prostaglandins**: By blocking COX, etodolac prevents the conversion of arachidonic acid into pro-inflammatory prostaglandins. * It is generally considered a **COX-1 sparing** drug rather than highly COX-2 selective in dogs. In horses, it does not exhibit much COX-2 selectivity. * Additionally, etodolac inhibits **macrophage chemotaxis**, which further blunts the inflammatory cascade at the site of tissue injury.

동물 종별 용량

Dogs

Treatment of pain and inflammation associated with osteoarthritis · 10-15 mg/kg · PO · once daily · Dogs less than 5 kg cannot be accurately dosed with EtoGesic tablets. Adjust dose to obtain satisfactory response, but do not exceed 15 mg/kg. For long-term therapy, reduce dose level to minimum effective dosage.
Treatment of pain and inflammation associated with osteoarthritis · 10-15 mg/kg · SC · once · Administer as a dorsoscapular subcutaneous injection. If needed, daily doses of tablets may begin 24 hours after the last injectable treatment. Use alternate injection sites.

용량은 면허 수의 전문가를 위한 임상 참고 자료입니다. 항상 최신 라벨과 개별 환자에 대해 확인하십시오.

투여 경로

POSC

금기

Known hypersensitivity to etodolac
Dogs less than 12 months of age
Breeding, pregnant, or lactating dogs (safe use not established)
Cats (highly sensitive to toxicity)

이상반응

Vomiting
Regurgitation
Diarrhea
Lethargy
Hypoproteinemia
Urticaria
Behavioral changes
Inappetence
Hepatotoxicity (rare)
Nephrotoxicity (rare)
Localized pain or tissue reactions at injection site
Decreased total serum T4
Keratoconjunctivitis sicca (KCS)

약물 상호작용

ACE Inhibitors (enalapril, benazepril) · May reduce antihypertensive effects and increase the risk for renal injury.
Aspirin · May decrease etodolac plasma levels and increase likelihood of GI adverse effects (blood loss). Concomitant use is not recommended.
Cyclosporine · May increase cyclosporine blood levels and increase the risk for nephrotoxicity.
Digoxin · May increase serum levels of digoxin. Use with caution in severe cardiac failure.
Furosemide & other diuretics · May reduce the saluretic and diuretic effects of furosemide.
Methotrexate · Serious toxicity has occurred with concomitant NSAID use.
Nephrotoxic agents (amphotericin B, aminoglycosides, cisplatin) · Potential for increased risk of nephrotoxicity.
Phenobarbital · May increase the metabolism of etodolac in dogs.
Probenecid · May cause a significant increase in serum levels and half-life of etodolac.
Warfarin · May increase the risk for bleeding.

모니터링

Baseline physical exam, CBC, Serum chemistry panel (liver and renal function), and Urinalysis
Reassess liver enzymes at one week of therapy
Tear production (Schirmer Tear Test) prior to and during therapy due to KCS risk
Clinical efficacy (pain scoring)
Signs of adverse reactions: inappetence, vomiting, melena, diarrhea, PU/PD, jaundice, lethargy

과용량

Etodolac has a relatively **narrow therapeutic window** in dogs. * **2.7X overdose (40 mg/kg/day)**: Can cause GI ulcers, weight loss, emesis, and local occult blood. * **5.3X overdose (80 mg/kg/day)**: Highly lethal; caused death or moribund state secondary to severe GI ulceration in safety studies. * **Feline Toxicity**: Cats are highly sensitive. Exposures have resulted in acute renal failure, anorexia, collapse, hyperkalemia, and hypersalivation. **Treatment**: Decontamination with emetics and/or activated charcoal may be appropriate for acute ingestions. Use gastrointestinal protectants for expected GI effects. If renal effects are anticipated, aggressive fluid diuresis is warranted.

VetSheet 약물 레퍼런스는 면허 수의 전문가를 위한 임상 의사결정 보조 도구이며, 전문적 판단이나 제조사의 최신 라벨을 대신하지 않습니다.